Fundraising Fox
/Companies
Sign in

Antabio

8 known investors

Find your way into Antabio

Sign up to see every warm intro you have to Antabio

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Antabio team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Antabio is a clinical-stage biopharmaceutical company developing novel antibacterial treatments for drug-resistant, Gram-negative bacterial infections identified as critical priorities by the WHO and CDC, with a focus on life-threatening hospital-acquired infections. Its lead program, Meropenem-Pilabactam, is a β-lactam/β-lactamase inhibitor combination for treating multidrug-resistant infections in hospital wards and ICUs.

BiotechHealthtech

Founders & leadership

MLMarc Lemonnier
Marc LemonnierChief Executive OfficerMarc Lemonnier is founding CEO of Antabio, a biopharmaceutical company developing treatments for drug-resistant bacterial infections. He has served as co-founder and board member of the BEAM Alliance, a European biotech consortium focused on antimicrobial resistance, and was a member of the Scientific Advisory Board of the Joint Programming Initiative on Antimicrobial Resistance.
RPRienk Pypstra
Rienk PypstraChief Medical Officer
GWGordon Waldron
Gordon WaldronChief Financial OfficerGordon Waldron has more than 30 years of experience in biotech, medtech, and high-tech sectors, with a background in M&A, financing, and business development including raising over €200M in venture capital and executing multiple exit transactions for biotech companies.
MZMagdalena Zalacain
Magdalena ZalacainChief Scientific OfficerMagdalena Zalacain is Chief Scientific Officer at Antabio and brings 25 years of experience in antibacterial drug discovery and development across the pharmaceutical industry, including expertise in target identification, lead optimization, and advancement of molecules through Phase I and II clinical studies. She has specialized in antibacterial discovery and antibiotic production and resistance in Streptomyces.

Investors · 8

BNP Paribas Développement✓ confirmed by AntabioParis

How we know: the company's own site · antabio.com · Not right? Tell us

IRDI SORIDEC GestionreportedToulouse · $216K – $16.2M

How we know: funding news · biocentury.com · Not right? Tell us

Omnes CapitalreportedParis

How we know: antabio.com · Not right? Tell us

Also in the syndicate · 4

Galia GestioniXO Private EquitySham Innovation SantéTurenne Capital

Funding

SEC filings, press & company announcements

Source: company announcements and press reports — follow each round's link for the claim.

In the news

Antabio Completes €12.5M Series A Funding Roundantabio.com · Jul 2018

Frequently asked questions

What does Antabio do?
Antabio is a clinical-stage biopharmaceutical company developing novel antibacterial treatments for drug-resistant, Gram-negative bacterial infections identified as critical priorities by the WHO and CDC, with a focus on life-threatening hospital-acquired infections. Its lead program, Meropenem-Pilabactam, is a β-lactam/β-lactamase inhibitor combination for treating multidrug-resistant infections in hospital wards and ICUs.
Who founded Antabio?
Antabio was founded by Marc Lemonnier.
Who are Antabio's investors?
Antabio's investors include AMR Action Fund, BNP Paribas Développement, IRDI SORIDEC Gestion, Omnes Capital.